<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35486279</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1614-7499</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>29</Day>
            </PubDate>
          </JournalIssue>
          <Title>Environmental science and pollution research international</Title>
          <ISOAbbreviation>Environ Sci Pollut Res Int</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11356-022-20445-1</ELocationID>
        <Abstract>
          <AbstractText>Diabetes is a global health concern that has affected almost 415 million people globally. Bromocriptine is a dopamine D2 agonist, which is a Food and Drug Administration (FDA)-approved drug to treat type 2 diabetes mellitus (T2DM) patients. However, it is considered that a novel treatment therapy is required which can be used in the treatment of diabetes with or without other antidiabetic agents. Dopamine agonists are usually used in neurological disorders like Parkinson's disease (PD), restless leg syndrome, and hyperprolactinemia. However, dopamine agonists including bromocriptine and cabergoline are also effective in reducing the glycemic level in T2DM patients. Bromocriptine was formerly used for the treatment of PD, hyperprolactinemia, and restless leg syndrome, but now it is used for improving glycemic levels as well as reducing free fatty acids and triglycerides. In addition, cabergoline has been found to be effective in glycemic control, but this drug is yet to be approved by the FDA due to its limitations and lack of study. Findings of the clinical trials of bromocriptine have suggested that it reduces almost 0.4-0.8% glycated hemoglobin and cardiovascular risk by 40% in insulin-resistant patients. Moreover, the safe use of bromocriptine in obese T2DM patients makes it a more attractive option as it causes weight loss. Indeed, bromocriptine is a novel therapy for T2DM patients, as its mechanism of action is unique in T2DM patients with minimal adverse effects. This review summarizes the potential of dopamine agonists in the treatment of T2DM.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kabir</LastName>
            <ForeName>Md Tanvir</ForeName>
            <Initials>MT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Brac University, 66 Mohakhali, Dhaka, 1212, Bangladesh.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferdous Mitu</LastName>
            <ForeName>Jannatul</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Brac University, 66 Mohakhali, Dhaka, 1212, Bangladesh.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akter</LastName>
            <ForeName>Raushanara</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Brac University, 66 Mohakhali, Dhaka, 1212, Bangladesh.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akhtar</LastName>
            <ForeName>Muhammad Furqan</ForeName>
            <Initials>MF</Initials>
            <AffiliationInfo>
              <Affiliation>Riphah Institute of Pharmaceutical Sciences, Riphah International University Lahore Campus, Lahore, Pakistan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saleem</LastName>
            <ForeName>Ammara</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Faculty of Pharmaceutical Sciences, Government College University Faisalabad, Faisalabad, Pakistan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Al-Harrasi</LastName>
            <ForeName>Ahmed</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Natural &amp; Medical Sciences Research Center, University of Nizwa, 616 Birkat Al Mauz, P.O. Box 33, Nizwa, Oman.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bhatia</LastName>
            <ForeName>Saurabh</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Natural &amp; Medical Sciences Research Center, University of Nizwa, 616 Birkat Al Mauz, P.O. Box 33, Nizwa, Oman.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Health Science, University of Petroleum and Energy Studies, Prem Nagar, Dehradun, Uttarakhand, 248007, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rahman</LastName>
            <ForeName>Md Sohanur</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, Trust University, Barishal, Ruiya, Nobogram Road, Barishal, 8200, Bangladesh.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Damiri</LastName>
            <ForeName>Fouad</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Biomolecules and Organic Synthesis (BIOSYNTHO), Department of Chemistry, Faculty of Sciences Ben M'Sick, University Hassan II of Casablanca, Casablanca, Morocco.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Berrada</LastName>
            <ForeName>Mohammed</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Biomolecules and Organic Synthesis (BIOSYNTHO), Department of Chemistry, Faculty of Sciences Ben M'Sick, University Hassan II of Casablanca, Casablanca, Morocco.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rahman</LastName>
            <ForeName>Md Habibur</ForeName>
            <Initials>MH</Initials>
            <Identifier Source="ORCID">0000-0001-6099-5693</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Southeast University, Banani, Dhaka, 1213, Bangladesh. pharmacisthabib@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Global Medical Science, Wonju College of Medicine, Yonsei University, Wonju, 26426, Gangwon-do, Korea. pharmacisthabib@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Environ Sci Pollut Res Int</MedlineTA>
        <NlmUniqueID>9441769</NlmUniqueID>
        <ISSNLinking>0944-1344</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Bromocriptine</Keyword>
        <Keyword MajorTopicYN="N">Cabergoline</Keyword>
        <Keyword MajorTopicYN="N">Dopamine agonist</Keyword>
        <Keyword MajorTopicYN="N">Triglycerides</Keyword>
        <Keyword MajorTopicYN="N">Type 2 diabetes</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>11</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35486279</ArticleId>
        <ArticleId IdType="doi">10.1007/s11356-022-20445-1</ArticleId>
        <ArticleId IdType="pii">10.1007/s11356-022-20445-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Akter R, Chowdhury MAR, &amp; Habib Ur Rahman M (2020) Flavonoids and polyphenolic compounds as potential talented agents for the treatment of Alzheimer’s disease with their antioxidant activities. Curr Pharm Des</Citation>
        </Reference>
        <Reference>
          <Citation>Akter R, Rahman H, Behl T, Chowdhury MAR, Manirujjaman M, Bulbul IJ, Elshenaw SE, Tit DM, &amp; Bungau S (2021) Prospective role of polyphenolic compounds in the treatment of neurodegenerative diseases. CNS Neurol Disord Drug Targets, 20(5). https://doi.org/10.2174/1871527320666210218084444</Citation>
        </Reference>
        <Reference>
          <Citation>Al-Lawati JA (2017) Diabetes mellitus: a local and global public health emergency! Oman Med J 32(3):177–179. https://doi.org/10.5001/omj.2017.34</Citation>
        </Reference>
        <Reference>
          <Citation>Aminorroaya A, Janghorbani M, Ramezani M, Haghighi S, Amini M (2004) Does bromocriptine improve glycemic control of obese type-2 diabetics? Horm Res 62(2):55–59. https://doi.org/10.1159/000078932</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000078932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arya A, Chahal R, Nanda A, Kaushik D, Bin-Jumah M, Rahman MH, Abdel-Daim MM, &amp; Mittal V (2021) Statistically designed extraction of herbs using ultrasound waves: a review. Curr Pharm Des 27(34). https://doi.org/10.2174/1381612827666210222114441</Citation>
        </Reference>
        <Reference>
          <Citation>Aslanoglou D, Bertera S, Sánchez-Soto M, Benjamin Free R, Lee J, Zong W, Xue X, Shrestha S, Brissova M, Logan RW, Wollheim CB, Trucco M, Yechoor VK, Sibley DR, Bottino R, Freyberg Z (2021) Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors. Transl Psychiatry 11(1):1–18. https://doi.org/10.1038/s41398-020-01171-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41398-020-01171-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Assad HC, Mosah HA, Hashim HM, &amp; Khazaal FA (2014) Effect of cabergoline added to metformin on glycemic control, insulin resistance and beta cell function in obese type 2 diabetic patients. Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc, 14.</Citation>
        </Reference>
        <Reference>
          <Citation>Association AD (2009) Diagnosis and classification of diabetes mellitus. Diabetes Care 32(Suppl 1):S62. https://doi.org/10.2337/DC09-S062</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/DC09-S062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bahar A, Kashi Z, Daneshpour E, Akha O, &amp; Ala S (2016) Effects of cabergoline on blood glucose levels in type 2 diabetic patients: a double-blind controlled clinical trial. Medicine (United States), 95(40). https://doi.org/10.1097/MD.0000000000004818</Citation>
        </Reference>
        <Reference>
          <Citation>Bellou V, Belbasis L, Tzoulaki I, &amp; Evangelou E (2018) Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses. In PLoS One. Public Library of Science. 13 3 e0194127 https://doi.org/10.1371/journal.pone.0194127</Citation>
        </Reference>
        <Reference>
          <Citation>Ben-Jonathan N, Hugo ER, Brandebourg TD, &amp; LaPensee CR (2006) Focus on prolactin as a metabolic hormone. In Trends in Endocrinology and Metabolism. Trends Endocrinol Metab 17 3 110–116 https://doi.org/10.1016/j.tem.2006.02.005</Citation>
        </Reference>
        <Reference>
          <Citation>Berke EM, Koepsell TD, Moudon AV, Hoskins RE, Larson EB (2007) Association of the built environment with physical activity and obesity in older persons. Am J Public Health 97(3):486–492. https://doi.org/10.2105/AJPH.2006.085837</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2105/AJPH.2006.085837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhatia A, Lenchner JR, &amp; Saadabadi A (2021) Biochemistry, dopamine receptors. StatPearls</Citation>
        </Reference>
        <Reference>
          <Citation>Bhattacharya T, Dey PS, Akter R, Kabir T, Rahman H, &amp; Rauf A (2021) Effect of natural leaf extracts as phytomedicine in curing geriatrics. Exp Gerontol 150. https://doi.org/10.1016/j.exger.2021.111352</Citation>
        </Reference>
        <Reference>
          <Citation>Bi Y, Wang T, Xu M, Xu Y, Li M, Lu J, Zhu X, Ning G (2012) Advanced research on risk factors of type 2 diabetes. Diabetes Metab Res Rev 28(SUPPL,2):32–39. https://doi.org/10.1002/dmrr.2352</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dmrr.2352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Black JL, &amp; Macinko J (2008) Neighborhoods and obesity. In Nutrition Reviews. Nutr Rev 66 1 2–20. https://doi.org/10.1111/j.1753-4887.2007.00001.x</Citation>
        </Reference>
        <Reference>
          <Citation>Bloomgarden Z, &amp; Guang N (2010) Hypertension in patients with diabetes: questions. In Journal of Diabetes. J Diabetes 2 3 128–129. https://doi.org/10.1111/j.1753-0407.2010.00083.x</Citation>
        </Reference>
        <Reference>
          <Citation>Booth KM, Pinkston MM, Poston WSC (2005) Obesity and the built environment. J Am Diet Assoc 105(5 SUPPL.):110–117. https://doi.org/10.1016/j.jada.2005.02.045</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jada.2005.02.045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borelli MI, &amp; Gagliardino JJ (2001) Possible modulatory effect of endogenous islet catecholamines on insulin secretion. BMC Endocr Disord 1(1). https://doi.org/10.1186/1472-6823-1-1</Citation>
        </Reference>
        <Reference>
          <Citation>Borelli MI, Rubio M, García ME, Flores LE, &amp; Gagliardino JJ (2003) Tyrosine hydroxylase activity in the endocrine pancreas: changes induced by short-term dietary manipulation. BMC Endocr Disord 3(1). https://doi.org/10.1186/1472-6823-3-2</Citation>
        </Reference>
        <Reference>
          <Citation>Boundy VA, Cincotta AH (2000) Hypothalamic adrenergic receptor changes in the metabolic syndrome of genetically obese ( ob / ob ) mice. Am J Physiol-Regul Integr Comp Physiol 279(2):R505–R514. https://doi.org/10.1152/ajpregu.2000.279.2.R505</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpregu.2000.279.2.R505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brooks DJ (2000) Dopamine agonists: their role in the treatment of Parkinson’s disease. In Journal of Neurology Neurosurgery and Psychiatry. BMJ Publishing Group 68 6 685–689. https://doi.org/10.1136/jnnp.68.6.685</Citation>
        </Reference>
        <Reference>
          <Citation>Callier S, Snapyan M, Le Crom S, Prou D, Vincent JD, &amp; Vernier P (2003) Evolution and cell biology of dopamine receptors in vertebrates. In Biology of the Cell. Biol Cell 95 7 489–502. https://doi.org/10.1016/S0248-4900(03)00089-3</Citation>
        </Reference>
        <Reference>
          <Citation>Cantley J, &amp; Ashcroft FM (2015) Q&amp;A: insulin secretion and type 2 diabetes: why do β-cells fail?. BMC Biology, 13(1). https://doi.org/10.1186/S12915-015-0140-6</Citation>
        </Reference>
        <Reference>
          <Citation>Chan JCN, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, &amp; Hu FB (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. In JAMA - Journal of the American Medical Association. JAMA 301 20 2129–2140. https://doi.org/10.1001/jama.2009.726</Citation>
        </Reference>
        <Reference>
          <Citation>Chatterjee S, Khunti K, Davies MJ (2017) Type 2 diabetes. The Lancet 389(10085):2239–2251. https://doi.org/10.1016/S0140-6736(17)30058-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(17)30058-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, Cohrs CM, Stertmann J, Bozsak R, Speier S (2017) Human beta cell mass and function in diabetes: recent advances in knowledge and technologies to understand disease pathogenesis. Mol Metab 6(9):943–957. https://doi.org/10.1016/J.MOLMET.2017.06.019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.MOLMET.2017.06.019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Huang Y, Li X, Xu M, Bi Y, Zhang Y, Gu W, Ning G (2009) Association of arterial stiffness with HbA1c in 1,000 type 2 diabetic patients with or without hypertension. Endocrine 36(2):262–267. https://doi.org/10.1007/s12020-009-9221-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-009-9221-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chio CL, Drong RF, Riley DT, Gill GS, Slightom JL, Huff RM (1994a) D4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells. J Biol Chem 269(16):11813–11819. https://doi.org/10.1016/s0021-9258(17)32645-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0021-9258(17)32645-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chio CL, Lajiness ME, Huff RM (1994b) Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol 45(1):51–60</Citation>
        </Reference>
        <Reference>
          <Citation>Choi J, Choi JY, Lee SA, Lee KM, Shin A, Oh J, Park J, Song M, Yang JJ, Lee JK, Kang D (2019) Association between family history of diabetes and clusters of adherence to healthy behaviors: cross-sectional results from the Health Examinees-Gem (HEXA-G) study. BMJ Open 9(6):e025477. https://doi.org/10.1136/BMJOPEN-2018-025477</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/BMJOPEN-2018-025477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cincotta AH, Luo S, Zhang Y, Liang Y, Bina KG, Jetton TL, Scislowski PWD (2000) Chronic infusion of norepinephrine into the VMH of normal rats induces the obese glucose-intolerant state. Am J Physiol-Reg Integr Comp Physiol 278(2):R435–R444. https://doi.org/10.1152/ajpregu.2000.278.2.R435</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpregu.2000.278.2.R435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cincotta AH, MacEachern TA, Meier AH (1993a) Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol-Endocr Metab 264(2):27–32. https://doi.org/10.1152/ajpendo.1993.264.2.e285</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpendo.1993.264.2.e285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cincotta AH, Meier AH (1996) Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 19(6):667–670. https://doi.org/10.2337/diacare.19.6.667</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diacare.19.6.667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cincotta AH, Meier AH, Cincotta MJ (1999) Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes In Expert Opinion on Investigational Drugs. Expert Opin Investig Drugs 8(10):1683–1707. https://doi.org/10.1517/13543784.8.10.1683</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/13543784.8.10.1683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cincotta AH, Schiller BC, Landry RJ, Herbert SJ, Miers WR, Meier AH (1993b) Circadian neuroendocrine role in age-related changes in body fat stores and insulin sensitivity of the Male sprague-dawley rat. Chronobiol Int 10(4):244–258. https://doi.org/10.1080/07420529309059707</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/07420529309059707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Civelli O, Bunzow JR, Grandy DK (1993) Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 33(1):281–307. https://doi.org/10.1146/annurev.pa.33.040193.001433</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.pa.33.040193.001433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clausius N, Born C, &amp; Grunze H (2009) Die bedeutung von dopaminagonisten in der behandlung der depression. In Neuropsychiatrie. Neuropsychiatr 23 1 15–25. https://doi.org/10.5414/nepband23015</Citation>
        </Reference>
        <Reference>
          <Citation>Cohen AI, Todd RD, Harmon S, O’Malley KL (1992) Photoreceptors of mouse retinas possess D4 receptors coupled to adenylate cyclase. Proc Natl Acad Sci USA 89(24):12093–12097. https://doi.org/10.1073/pnas.89.24.12093</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.89.24.12093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colao A, Di Sarno A, Guerra E, De Leo M, Mentone A, &amp; Lombardi G (2006) Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. In Nature Clinical Practice Endocrinology and Metabolism. Nat Clin Pract Endocrinol Metab 2 4 200–210. https://doi.org/10.1038/ncpendmet0160</Citation>
        </Reference>
        <Reference>
          <Citation>Daly JM, Hartz AJ, Xu Y, Levy BT, James PA, Merchant ML, Garrett RE (2009) An assessment of attitudes, behaviors, and outcomes of patients with type 2 diabetes. J Am Board Fam Med 22(2):280–290. https://doi.org/10.3122/jabfm.2009.03.080114</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3122/jabfm.2009.03.080114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K (2020) The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Front Immunol 11:1582. https://doi.org/10.3389/FIMMU.2020.01582/BIBTEX</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/FIMMU.2020.01582/BIBTEX</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dearry A, Gingrich JA, Falardeau P, Fremeau RT, Bates MD, Caron MG (1990) Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 347(6288):72–76. https://doi.org/10.1038/347072a0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/347072a0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Defronzo RA (2009) From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58(4):773–795. https://doi.org/10.2337/db09-9028</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db09-9028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeFronzo RA (2011) Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. In Diabetes Care. American Diabetes Association 34 4789–794. https://doi.org/10.2337/dc11-0064</Citation>
        </Reference>
        <Reference>
          <Citation>DeFronzo RA, Ferrannini E (1991) Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14(3):173–194. https://doi.org/10.2337/diacare.14.3.173</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diacare.14.3.173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deshpande AD, Harris-Hayes M, Schootman M (2008) Epidemiology of diabetes and diabetes-related complications. Phys Ther 88(11):1254. https://doi.org/10.2522/PTJ.20080020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2522/PTJ.20080020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dirir AM, Daou M, Yousef AF, &amp; Yousef LF (2021) A review of alpha-glucosidase inhibitors from plants as potential candidates for the treatment of type-2 diabetes. Phytochem Rev 2021, 1–31. https://doi.org/10.1007/S11101-021-09773-1</Citation>
        </Reference>
        <Reference>
          <Citation>Durant S, Coulaud J, Homo-Delarche F (2007) Bromocriptine-induced hyperglycemia in nonobese diabetic mice: kinetics and mechanisms of action. Rev Diabet Stud 4(3):185–194. https://doi.org/10.1900/RDS.2007.4.185</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1900/RDS.2007.4.185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiory F, Perruolo G, Cimmino I, Cabaro S, Pignalosa FC, Miele C, Beguinot F, Formisano P, Oriente F (2019) The relevance of insulin action in the dopaminergic system. Front Neurosci 13:868. https://doi.org/10.3389/FNINS.2019.00868/BIBTEX</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/FNINS.2019.00868/BIBTEX</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B (2014) Metformin: from mechanisms of action to therapies. Cell Metab 20(6):953–966. https://doi.org/10.1016/J.CMET.2014.09.018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.CMET.2014.09.018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fousteri G, Ippolito E, Ahmed R, Hamad ARA (2017) Beta-cell specific autoantibodies: are they just an indicator of type 1 diabetes? Curr Diabetes Rev 13(3):322–329. https://doi.org/10.2174/1573399812666160427104157</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1573399812666160427104157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu Z, Gilbert ER, Liu D (2013) Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes. Curr Diabetes Rev 9(1):25. https://doi.org/10.2174/15733998130104</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/15733998130104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gallen I (2013) Type 1 diabetes: clinical management of the athlete. Type 1 Diabetes: Clinical Management of the Athlete, 383(9911), 1–223. https://doi.org/10.1007/978-0-85729-754-9</Citation>
        </Reference>
        <Reference>
          <Citation>Garber AJ, Blonde L, Bloomgarden ZT, Handelsman Y, Dagogo-Jack S (2013) The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocr Pract 19(1):100–106. https://doi.org/10.4158/EP12325.OR</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4158/EP12325.OR</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia Barrado MJ, Iglesias Osma MC, Blanco EJ, Carretero Hernández M, Sánchez Robledo V, Catalano Iniesta L, Carrero S, Carretero J (2015) Dopamine modulates insulin release and is involved in the survival of rat pancreatic beta cells. PLoS ONE 10(4):e0123197. https://doi.org/10.1371/journal.pone.0123197</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0123197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaziano JM, Cincotta AH, O’Connor CM, Ezrokhi M, Rutty D, Ma ZJ, Scranton RE (2010) Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 33(7):1503–1508. https://doi.org/10.2337/dc09-2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc09-2009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerich JE (2000) Insulin resistance is not necessarily an essential component of type 2 diabetes. J Clin Endocrinol Metab 85(6):2113–2115. https://doi.org/10.1210/JCEM.85.6.6646</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/JCEM.85.6.6646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghosh A, Sengupta N, Sahana P, Giri D, Sengupta P, Das N (2014) Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: a randomized open labeled phase IV clinical trial. Indian J Pharmacol 46(1):24. https://doi.org/10.4103/0253-7613.125160</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0253-7613.125160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibson CD, Karmally W, Mcmahon DJ, Wardlaw SL, Korner J (2012) Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes Metab 14(4):335–340. https://doi.org/10.1111/j.1463-1326.2011.01534.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1463-1326.2011.01534.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gingrich JA, &amp; Caron MG (1993) Recent advances in the molecular biology of dopamine receptors. In Annual Review of Neuroscience. Annu Rev Neurosci. 16 299–231. https://doi.org/10.1146/annurev.ne.16.030193.001503</Citation>
        </Reference>
        <Reference>
          <Citation>Gong L, Feng D, Wang T, Ren Y, Liu Y, Wang J (2020) Inhibitors of α-amylase and α-glucosidase: potential linkage for whole cereal foods on prevention of hyperglycemia. Food Sci Nutr 8(12):6320–6337. https://doi.org/10.1002/fsn3.1987</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/fsn3.1987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Govender P, Elmezughi K, Esterhuizen T, Paruk I, James Pirie F, &amp; Ahmed Motala A (2018) Characteristics of subjects with diabetes mellitus diagnosed before 35 years of age presenting to a tertiary diabetes clinic in Durban, South Africa, from 2003 to 2016. 23(1), 26–31. https://doi.org/10.1080/16089677.2017.1417779</Citation>
        </Reference>
        <Reference>
          <Citation>Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L, Fischer JB, Burke-Howie KJ, Bunzow JR, Server AC, Civelli O (1989) Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci USA 86(24):9762–9766. https://doi.org/10.1073/pnas.86.24.9762</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.86.24.9762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gross B, Pawlak M, Lefebvre P, Staels B (2016) PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol 13(1):36–49. https://doi.org/10.1038/nrendo.2016.135</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrendo.2016.135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gui MH, Qin GY, Ning G, Hong J, Li XY, Lü AK, Shen WF, Gao X (2009) The comparison of coronary angiographic profiles between diabetic and nondiabetic patients with coronary artery disease in a Chinese population. Diabetes Res Clin Pract 85(2):213–219. https://doi.org/10.1016/j.diabres.2009.05.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.diabres.2009.05.010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guillausseau PJ, Meas T, Virally M, Laloi-Michelin M, Médeau V, Kevorkian JP (2008) Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab 34(SUPPL. 2):S43–S48. https://doi.org/10.1016/S1262-3636(08)73394-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1262-3636(08)73394-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta A, Behl T, Aleya L, Rahman MH, Yadav HN, Pal G, Kaur I, &amp; Arora S (2021) Role of UPP pathway in amelioration of diabetes-associated complications. In Environmental Science and Pollution Research 28 16. https://doi.org/10.1007/s11356-021-12781-5</Citation>
        </Reference>
        <Reference>
          <Citation>Gupta V (2013) Glucagon-like peptide-1 analogues: an overview. Indian J Endocrinol Metab 17(3):413. https://doi.org/10.4103/2230-8210.111625</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/2230-8210.111625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gurevich EV, Gainetdinov RR, Gurevich VV (2016) G protein-coupled receptor kinases as regulators of dopamine receptor functions. Pharmacol Res 111:1. https://doi.org/10.1016/J.PHRS.2016.05.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.PHRS.2016.05.010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halimi S, Schweizer A, Minic B, Foley J, Dejager S (2008) Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag 4(3):481. https://doi.org/10.2147/VHRM.S2503</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/VHRM.S2503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haslam DW, James WPT (2005) Obesity. Lancet 366(9492):1197–1209. https://doi.org/10.1016/S0140-6736(05)67483-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(05)67483-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS (1991) Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 325(3):147–152. https://doi.org/10.1056/nejm199107183250302</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejm199107183250302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holt RIG, Barnett AH, &amp; Bailey CJ (2010) Bromocriptine: old drug, new formulation and new indication. In Diabetes, Obesity and Metabolism. Blackwell Publishing Ltd 12 12 1048–1057. https://doi.org/10.1111/j.1463-1326.2010.01304.x</Citation>
        </Reference>
        <Reference>
          <Citation>Hossain P, Kawar B, El Nahas M (2007) Obesity and diabetes in the developing world — a growing challenge. N Engl J Med 356(3):213–215. https://doi.org/10.1056/NEJMp068177</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMp068177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC (2001) Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345(11):790–797. https://doi.org/10.1056/nejmoa010492</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmoa010492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Chen Y, Xu M, Gu W, Bi Y, Li X, Ning G (2010) Low-grade albuminuria is associated with carotid intima-media thickness in Chinese type 2 diabetic patients. J Clin Endocrinol Metab 95(11):5122–5128. https://doi.org/10.1210/jc.2010-0544</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2010-0544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikeda H, Yonemochi N, Mikami R, Abe M, Kawamura M, Natsume R, Sakimura K, Waddington JL, Kamei J (2020) Central dopamine D2 receptors regulate plasma glucose levels in mice through autonomic nerves. Sci Rep 10(1):1–11. https://doi.org/10.1038/s41598-020-79292-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-79292-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikemoto S (2007) Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev 56(1):27. https://doi.org/10.1016/J.BRAINRESREV.2007.05.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.BRAINRESREV.2007.05.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inzucchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287(3):360–372. https://doi.org/10.1001/JAMA.287.3.360</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/JAMA.287.3.360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irons BK, Minze MG (2014) Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. Diabetes Metab Syndr Obes: Targets and Therapy 7:15. https://doi.org/10.2147/DMSO.S38753</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/DMSO.S38753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson DM, &amp; Westlind-Danielsson A (1994) Dopamine receptors: molecular biology, biochemistry and behavioural aspects. In Pharmacology and Therapeutics. Pharmacol Ther. 64 2 291–370. https://doi.org/10.1016/0163-7258(94)90041-8</Citation>
        </Reference>
        <Reference>
          <Citation>Jackson ME, Moghaddam B (2001) Amygdala regulation of nucleus accumbens dopamine output is governed by the prefrontal cortex. J Neurosci 21(2):676. https://doi.org/10.1523/JNEUROSCI.21-02-00676.2001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.21-02-00676.2001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones AP, Pothos EN, Rada P, Olster DH, Hoebel BG (1995) Maternal hormonal manipulations in rats cause obesity and increase medial hypothalamic norepinephrine release in male offspring. Dev Brain Res 88(2):127–131. https://doi.org/10.1016/0165-3806(95)00078-R</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0165-3806(95)00078-R</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kabir MT, Tabassum N, Uddin MS, Aziz F, Behl T, Mathew B, Rahman MH, Akter R, Rauf A, &amp; Aleya L (2021) Therapeutic potential of polyphenols in the management of diabetic neuropathy. Evid-Based Complement Alternat Med2021. https://doi.org/10.1155/2021/9940169</Citation>
        </Reference>
        <Reference>
          <Citation>Kahn SE, Cooper ME, &amp; Del Prato S (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. In The Lancet. Lancet Publishing Group 383 9922 1068–1083. https://doi.org/10.1016/S0140-6736(13)62154-6</Citation>
        </Reference>
        <Reference>
          <Citation>Kalra S, Kalra B, Agrawal N, Kumar S (2011) Dopamine: the forgotten felon in type 2 diabetes. Recent Pat Endocr, Metab Immune Drug Discovery 5(1):61–65. https://doi.org/10.2174/187221411794351842</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/187221411794351842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamath V, Jones CN, Yip JC, Varasteh BB, Cincotta AH, Reaven GM, Chen YDI (1997) Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care 20(11):1697–1701. https://doi.org/10.2337/diacare.20.11.1697</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diacare.20.11.1697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kansra AR, Lakkunarajah S, Jay MS (2021) Childhood and adolescent obesity: a review. Front Pediatr 8:866. https://doi.org/10.3389/FPED.2020.581461/BIBTEX</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/FPED.2020.581461/BIBTEX</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karthika C, Hari B, Rahman MH, Akter R, Najda A, Albadrani GM, Sayed AA, Akhtar MF, &amp; Abdel-Daim MM (2021) Multiple strategies with the synergistic approach for addressing colorectal cancer. In Biomedicine and Pharmacotherapy 140. https://doi.org/10.1016/j.biopha.2021.111704</Citation>
        </Reference>
        <Reference>
          <Citation>Kerr JL, Timpe EM, &amp; Petkewicz KA (2010) Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. In Annals of Pharmacotherapy. Ann Pharmacother 44 11 1777–1785. https://doi.org/10.1345/aph.1P271</Citation>
        </Reference>
        <Reference>
          <Citation>Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, Dawant B, Zald D, Meltzer HY (2009) Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiat 65(12):1024. https://doi.org/10.1016/J.BIOPSYCH.2008.12.029</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.BIOPSYCH.2008.12.029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Kaabi JA (2020) Epidemiology of type 2 diabetes – global burden of disease and forecasted trends. J Epidemiol Glob Health 10(1):107. https://doi.org/10.2991/JEGH.K.191028.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2991/JEGH.K.191028.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim K-S, Oh H-J, Kim J-W, Lee Y-K, Kim S-K, Park S-W, Kim Y-L, Park W-K, Cho Y-W (2010) The clinical characteristics of the newly diagnosed early onset (&lt; 40 years old) diabetes in outpatients’ clinic. Korean Diabetes J 34(2):119–125. https://doi.org/10.4093/KDJ.2010.34.2.119</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4093/KDJ.2010.34.2.119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitamura T, Kitamura Y, Kuroda S, Hino Y, Ando M, Kotani K, Konishi H, Matsuzaki H, Kikkawa U, Ogawa W, Kasuga M (1999) Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol Cell Biol 19(9):6286–6296. https://doi.org/10.1128/mcb.19.9.6286</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mcb.19.9.6286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein MO, Battagello DS, Cardoso AR, Hauser DN, Bittencourt JC, Correa RG (2018) Dopamine: functions, signaling, and association with neurological diseases. Cell Mol Neurobiol 39(1):31–59. https://doi.org/10.1007/S10571-018-0632-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/S10571-018-0632-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koch-Weser J, Parkes D (1979) Bromocriptine. N Engl J Med 301(16):873–878. https://doi.org/10.1056/NEJM197910183011606</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM197910183011606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koppes LLJ, Dekker JM, Hendriks HFJ, Bouter LM, &amp; Heine RJ (2005) Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies. In Diabetes Care. Diabetes Care 28 3 719–725. https://doi.org/10.2337/diacare.28.3.719</Citation>
        </Reference>
        <Reference>
          <Citation>Kraszewski KZ, Cincotta AH (2000) Increased responsiveness of ventromedial hypothalamic neurons to norepinephrine in obese versus lean mice: relation to the metabolic syndrome. Int J Mol Med 5(4):349–355. https://doi.org/10.3892/ijmm.5.4.349</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.5.4.349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kvist-Reimer M, Sundler F, Ahrén B (2002) Effects of chemical sympathectomy by means of 6-hydroxydopamine on insulin secretion and islet morphology in alloxan-diabetic mice. Cell Tissue Res 307(2):203–209. https://doi.org/10.1007/s00441-001-0496-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00441-001-0496-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kyrou I, Randeva HS, Tsigos C, Kaltsas G, &amp; Weickert MO (2018) Clinical problems caused by obesity. Endotext</Citation>
        </Reference>
        <Reference>
          <Citation>Lamos EM, Levitt DL, &amp; Munir KM (2016) A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters. In Primary Care Diabetes. Elsevier Ltd. 10 1 60–65. https://doi.org/10.1016/j.pcd.2015.10.008</Citation>
        </Reference>
        <Reference>
          <Citation>Li M, Li X, Zhang H, Lu Y (2018) Molecular mechanisms of metformin for diabetes and cancer treatment. Front Physiol 9:1039. https://doi.org/10.3389/FPHYS.2018.01039/BIBTEX</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/FPHYS.2018.01039/BIBTEX</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin MV, Bishop G, Benito-Herrero M (2010) Diabetic ketoacidosis in type 2 diabetics: a novel presentation of pancreatic adenocarcinoma. J Gen Intern Med 25(4):369. https://doi.org/10.1007/S11606-009-1237-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/S11606-009-1237-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu YP, Zhan WW, Zhang YF, Chen YH, Lin YY, Zhu Y, Ren XP, Li XY, Ning G (2007) Carotid intima-media thickness and stiffness in relation to type 2 diabetes in Chinese. Endocrine 31(3):289–293. https://doi.org/10.1007/s12020-007-0035-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-007-0035-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez Vicchi F, Luque GM, Brie B, Nogueira JP, Garcia Tornadu I, &amp; Becu-Villalobos D (2016) Dopaminergic drugs in type 2 diabetes and glucose homeostasis. In Pharmacological Research. Academic Press. 109 74–80. https://doi.org/10.1016/j.phrs.2015.12.029</Citation>
        </Reference>
        <Reference>
          <Citation>Luo S, Liang Y, Cincotta AH (1999a) Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology 69(3):160–166. https://doi.org/10.1159/000054415</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000054415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo S, Luo J, Cincotta AH (1999b) Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology 70(6):460–465. https://doi.org/10.1159/000054508</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000054508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo S, Luo J, Cincotta AH (2000) Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster. Chronobiol Int 17(2):155–172. https://doi.org/10.1081/CBI-100101040</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1081/CBI-100101040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo S, Luo J, Meier AH, Cincotta AH (1997) Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance. NeuroReport 8(16):3495–3499. https://doi.org/10.1097/00001756-199711100-00016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00001756-199711100-00016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo S, Meier AH, Cincotta AH (1998) Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology 68(1):1–10. https://doi.org/10.1159/000054344</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000054344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma X, Wang D, Zhao W, Xu L (2018) Deciphering the roles of PPARγ in adipocytes via dynamic change of transcription complex. Front Endocrinol 9(AUG):473. https://doi.org/10.3389/FENDO.2018.00473/BIBTEX</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/FENDO.2018.00473/BIBTEX</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahajan R (2009) Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes. Indian J Pharmacol 41(4):197. https://doi.org/10.4103/0253-7613.56070</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0253-7613.56070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mai P, &amp; Li SM (2013) Alkaloids derived from tryptophan: a focus on ergot alkaloids. Natural Products: Phytochemistry, Botany and Metabolism of Alkaloids, Phenolics and Terpenes, 683–714. https://doi.org/10.1007/978-3-642-22144-6_24</Citation>
        </Reference>
        <Reference>
          <Citation>Makrilakis K (2019) The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect. Int J Environ Res Public Health, 16(15). https://doi.org/10.3390/IJERPH16152720</Citation>
        </Reference>
        <Reference>
          <Citation>Malambo P, Kengne AP, De Villiers A, Lambert EV, &amp; Puoane T (2016) Built environment, selected risk factors and major cardiovascular disease outcomes: a systematic review. In PLoS ONE. Public Library of Science. 11 11. https://doi.org/10.1371/journal.pone.0166846</Citation>
        </Reference>
        <Reference>
          <Citation>Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, del Cañizo-Gómez FJ (2016) Update on the treatment of type 2 diabetes mellitus. World J Diabetes 7(17):354. https://doi.org/10.4239/WJD.V7.I17.354</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4239/WJD.V7.I17.354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, del Cañizo-Gómez FJ (2014) Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes 5(4):444. https://doi.org/10.4239/WJD.V5.I4.444</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4239/WJD.V5.I4.444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maurer G, Schreier E, Delaborde S, Loosli HR, Nufer R, Shukla AP (1982) Fate and disposition of bromocriptine in animals and man. I: structure elucidation of the metabolites. Eur J Drug Metab Pharmacokinet 7(4):281–292. https://doi.org/10.1007/BF03189631</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF03189631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maurer G, Schreier E, Delaborde S, Nufer R, Shukla AP (1983) Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism. Eur J Drug Metab Pharmacokinet 8(1):51–62. https://doi.org/10.1007/BF03189581</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF03189581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mcallister G, Knowles MR, Ward-Booth SM, Sinclair HA, Patel S, Marwood R, Emms F, Patel S, Smith A, Seabrook GR, Freedman SB (1995) Functional coupling of human d2, d3, and d4 dopamine receptors in HEK293 cells. J Recept Signal Transduction 15(1–4):267–281. https://doi.org/10.3109/10799899509045220</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10799899509045220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McHale M, Coldwell MC, Herrity N, Boyfield I, Winn FM, Ball S, Cook T, Robinson JH, Gloger IS (1994) Expression and functional characterisation of a synthetic version of the human D4 dopamine receptor in a stable human cell line. FEBS Lett 345(2–3):147–150. https://doi.org/10.1016/0014-5793(94)00423-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0014-5793(94)00423-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNeill LH, Kreuter MW, Subramanian SV (2006) Social environment and physical activity: a review of concepts and evidence. Soc Sci Med 63(4):1011–1022. https://doi.org/10.1016/j.socscimed.2006.03.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.socscimed.2006.03.012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meier AH, &amp; Cincotta AH (n.d.) Circadian rhythms regulate the-expression of the thrifty genotypelphenotype.</Citation>
        </Reference>
        <Reference>
          <Citation>Meier AH, Cincotta AH, Lovell WC (1992) Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 48(3):248–253. https://doi.org/10.1007/BF01930467</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01930467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meigs JB, Cupples LA, Wilson PWF (2000) Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes 49(12):2201–2207. https://doi.org/10.2337/diabetes.49.12.2201</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diabetes.49.12.2201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michael Gaziano J, Cincotta AH, Vinik A, Blonde L, Bohannon N, &amp; Scranton R (2012) Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc, 1(5). https://doi.org/10.1161/JAHA.112.002279</Citation>
        </Reference>
        <Reference>
          <Citation>Mishra A, Singh S, &amp; Shukla S (2018) Physiological and functional basis of dopamine receptors and their role in neurogenesis: possible implication for Parkinson’s disease. J Exp Neurosci 12. https://doi.org/10.1177/1179069518779829</Citation>
        </Reference>
        <Reference>
          <Citation>Missale C, Russel Nash S, Robinson SW, Jaber M, &amp; Caron MG (1998) Dopamine receptors: from structure to function. In Physiological Reviews. American Physiological Society. 78 1 189–225. https://doi.org/10.1152/physrev.1998.78.1.189</Citation>
        </Reference>
        <Reference>
          <Citation>Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Fard HH, Ghojazadeh M (2020) Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect 10(2):98. https://doi.org/10.34172/HPP.2020.18</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.34172/HPP.2020.18</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosah HA, &amp; Hashim H (2014) Effect of cabergoline on body weight, glycemic control and insulin resistance in patient with obesity and prediabetes. Undefined</Citation>
        </Reference>
        <Reference>
          <Citation>Motala AA, Busson M, Al-Harbi EM, Khuzam MAA, Al-Omari EMD, Arekat MR, Almawi WY (2005) Susceptible and protective human leukocyte antigen class II alleles and haplotypes in Bahraini type 2 (non-insulin-dependent) diabetes mellitus patients. Clin Diagn Lab Immunol 12(1):213. https://doi.org/10.1128/CDLI.12.1.213-217.2005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CDLI.12.1.213-217.2005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murea M, Ma L, &amp; Freedman BI (2012) Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. In Review of Diabetic Studies. Society for Biomedical Diabetes Research. 9 16–22. https://doi.org/10.1900/RDS.2012.9.6</Citation>
        </Reference>
        <Reference>
          <Citation>Neve KA, Seamans JK, &amp; Trantham-Davidson H (2004) Dopamine receptor signaling, 24(3), 165–205. https://doi.org/10.1081/RRS-200029981</Citation>
        </Reference>
        <Reference>
          <Citation>Novikov A, Vallon V (2016) SGLT2 inhibition in the diabetic kidney – an update. Curr Opin Nephrol Hypertens 25(1):50. https://doi.org/10.1097/MNH.0000000000000187</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MNH.0000000000000187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olivares-Hernández A, Figuero-Pérez L, Cruz-Hernandez JJ, Sarmiento RG, Usategui-Martin R, Miramontes-González JP (2021) Dopamine receptors and the kidney: an overview of health- and pharmacological-targeted implications. Biomolecules 11(2):254. https://doi.org/10.3390/BIOM11020254</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/BIOM11020254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oltmans GA (1983) Norepinephrine and dopamine levels in hypothalamic nuclei of the genetically obese mouse (ob/ob). Brain Res 273(2):369–373. https://doi.org/10.1016/0006-8993(83)90865-X</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-8993(83)90865-X</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA (2018) Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 17(1):1–14. https://doi.org/10.1186/S12933-018-0762-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/S12933-018-0762-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozery M, &amp; Wadhwa R (2020) Bromocriptine.In StatPearls. StatPearls Publishing</Citation>
        </Reference>
        <Reference>
          <Citation>Pálsson R, Patel UD (2014) Cardiovascular complications of diabetic kidney disease. Adv Chronic Kidney Dis 21(3):273. https://doi.org/10.1053/J.ACKD.2014.03.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/J.ACKD.2014.03.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park S, Kang S, Lee HW, Ko BS (2012) Central prolactin modulates insulin sensitivity and insulin secretion in diabetic rats. Neuroendocrinology 95(4):332–343. https://doi.org/10.1159/000336501</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000336501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paschou SA, Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C (2018) On type 1 diabetes mellitus pathogenesis. Endocr Connect 7(1):R38. https://doi.org/10.1530/EC-17-0347</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EC-17-0347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petersen MC, Shulman GI (2018) Mechanisms of insulin action and insulin resistance. Physiol Rev 98(4):2133–2223. https://doi.org/10.1152/PHYSREV.00063.2017/ASSET/IMAGES/LARGE/Z9J0041828680019.JPEG</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/PHYSREV.00063.2017/ASSET/IMAGES/LARGE/Z9J0041828680019.JPEG</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pijl H (2003) Reduced dopaminergic tone in hypothalamic neural circuits: expression of a “thrifty” genotype underlying the metabolic syndrome? Eur J Pharmacol 480(1–3):125–131. https://doi.org/10.1016/j.ejphar.2003.08.100</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2003.08.100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA (2000) Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 23(8):1154–1161. https://doi.org/10.2337/diacare.23.8.1154</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diacare.23.8.1154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potenza MN, Graminski GF, Schmauss C, Lerner MR (1994) Functional expression and characterization of human D2 and D3 dopamine receptors. J Neurosci 14(3 II):1463–1476. https://doi.org/10.1523/jneurosci.14-03-01463.1994</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/jneurosci.14-03-01463.1994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poursafa P, Mansourian M, Motlagh ME, Ardalan G, Kelishadi R (2014) Is air quality index associated with cardiometabolic risk factors in adolescents? The CASPIAN-III Study. Environ Res 134:105–109. https://doi.org/10.1016/j.envres.2014.07.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.envres.2014.07.010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Probst WC, Snyder LA, Schuster DI, Brosius J, Sealfon SC (1992) Sequence alignment of the G-protein coupled receptor superfamily. DNA Cell Biol 11(1):1–20. https://doi.org/10.1089/dna.1992.11.1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/dna.1992.11.1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pulgaron ER, Delamater AM (2014) Obesity and type 2 diabetes in children: epidemiology and treatment. Curr DiabRep 14(8):508. https://doi.org/10.1007/S11892-014-0508-Y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/S11892-014-0508-Y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quinn N (1995) Fortnightly review: drug treatment of Parkinson’s disease. BMJ 310(6979):575. https://doi.org/10.1136/bmj.310.6979.575</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.310.6979.575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raffo A, Hancock K, Polito T, Xie Y, Andan G, Witkowski P, Hardy M, Barba P, Ferrara C, Maffei A, Freeby M, Goland R, Leibel RL, Sweet IR, Harris PE (2008) Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine. J Endocrinol 198(1):41–49. https://doi.org/10.1677/JOE-07-0632</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1677/JOE-07-0632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahman M.H, Akter R, Bhattacharya T, Abdel-Daim MM, Alkahtani S, Arafah MW, Al-Johani NS, Alhoshani NM, Alkeraishan N, Alhenaky A, Abd‐Elkader OH, El-Seedi HR, Kaushik D, &amp; Mittal V (2020) Resveratrol and neuroprotection: impact and its therapeutic potential in Alzheimer’s disease. In Frontiers in Pharmacology 11. https://doi.org/10.3389/fphar.2020.619024</Citation>
        </Reference>
        <Reference>
          <Citation>Rahman MH, Bajgai J, Fadriquela A, Sharma S, Thi TT, Akter R, Goh SH, Kim CS, &amp; Lee KJ (2021) Redox effects of molecular hydrogen and its therapeutic efficacy in the treatment of neurodegenerative diseases. In Processes. 9 2. https://doi.org/10.3390/pr9020308</Citation>
        </Reference>
        <Reference>
          <Citation>Rajagopalan S, &amp; Brook RD (2012) Air pollution and type 2 diabetes: mechanistic insights. In Diabetes. Diabetes. 61 12 3037–3045. https://doi.org/10.2337/db12-0190</Citation>
        </Reference>
        <Reference>
          <Citation>Ramteke K, Ramanand J, Raparti G, Murthy M, Ramanand S, Jain S, Patwardhan M, Ghanghas R (2011) Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes. Indian J Endocrinol Metab 15(5):33. https://doi.org/10.4103/2230-8210.83062</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/2230-8210.83062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravindran S, &amp; Munusamy S (2021) Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease. J Cell Physiol, n/a(n/a). https://doi.org/10.1002/jcp.30621</Citation>
        </Reference>
        <Reference>
          <Citation>Reichmann H, Bilsing A, Ehret R, Greulich W, Schulz JB, Schwartz A, Rascol O (2006) Ergoline and non-ergoline derivatives in the treatment of Parkinson’s disease. J Neurol 253(4):iv36–iv38. https://doi.org/10.1007/S00415-006-4009-Z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/S00415-006-4009-Z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rena G, Hardie DG, Pearson ER (2017) The mechanisms of action of metformin. Diabetologia 60(9):1577. https://doi.org/10.1007/S00125-017-4342-Z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/S00125-017-4342-Z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renalds A, Smith TH, &amp; Hale PJ (2010a) A systematic review of built environment and health. In Family and Community Health. Fam Community Health. 33 1 68–78. https://doi.org/10.1097/FCH.0b013e3181c4e2e5</Citation>
        </Reference>
        <Reference>
          <Citation>Renalds A, Smith TH, Hale PJ (2010b) A systematic review of built environment and health. Fam Community Health 33(1):68–78. https://doi.org/10.1097/FCH.0b013e3181c4e2e5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/FCH.0b013e3181c4e2e5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rines AK, Sharabi K, Tavares CDJ, Puigserver P (2016) Targeting hepatic glucose output in the treatment of type 2 diabetes. Nat Rev Drug Discovery 15(11):786. https://doi.org/10.1038/NRD.2016.151</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/NRD.2016.151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson SW, Caron MG (1996) Chimeric D2/D3 dopamine receptors efficiently inhibit adenylyl cyclase in HEK 293 cells. J Neurochem 67(1):212–219. https://doi.org/10.1046/j.1471-4159.1996.67010212.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1471-4159.1996.67010212.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS (2009) Statement by an American association of clinical endocrinologists / American college of endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 15(6):540–559. https://doi.org/10.4158/EP.15.6.540</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4158/EP.15.6.540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Röder PV, Wu B, Liu Y, Han W (2016a) Pancreatic regulation of glucose homeostasis. Exp Mol Med 48(3):e219–e219. https://doi.org/10.1038/emm.2016.6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/emm.2016.6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Röder PV, Wu B, Liu Y, &amp; Han W (2016b) Pancreatic regulation of glucose homeostasis. In Experimental &amp; molecular medicine. Korean Society for Biochemistry and Molecular Biology. 48 3 e219. https://doi.org/10.1038/emm.2016b.6</Citation>
        </Reference>
        <Reference>
          <Citation>Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A (2020) Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol 17(3):150–161. https://doi.org/10.1038/s41574-020-00443-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41574-020-00443-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, Kawamori R, Edwards H (2008) Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93(10):3671–3689. https://doi.org/10.1210/jc.2008-0222</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2008-0222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy P, Koetter P, Cunningham J, Komanduri S, Cinicola J (2021) A rare case of diabetic ketoacidosis presenting with severe hypertriglyceridemia requiring plasmapheresis in an adult with type-2 diabetes mellitus: Case report. Medicine 100(23):e26237. https://doi.org/10.1097/MD.0000000000026237</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000026237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saadat N, Esmaily H, Abbasinazari M, Tohidi M, Salamzadeh J, Hadaegh F, Tolabi M, Kalantar-Hormozi M, Dibaj M (2015) Does twice-weekly cabergoline improve anthropometrical and biochemical profiles in prediabetes? A randomized double-blind clinical trial pilot study. Iranian J Pharm Res 14(14):77–86. https://doi.org/10.22037/ijpr.2015.1715</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.22037/ijpr.2015.1715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saeedi P, Salpea P, Karuranga S, Petersohn I, Malanda B, Gregg EW, Unwin N, Wild SH, &amp; Williams R (2020) Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 162. https://doi.org/10.1016/J.DIABRES.2020.108086</Citation>
        </Reference>
        <Reference>
          <Citation>Saelens BE, Sallis JF, Black JB, Chen D (2003) Neighborhood-based differences in physical activity: an environment scale evaluation. Am J Public Health 93(9):1552–1558. https://doi.org/10.2105/AJPH.93.9.1552</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2105/AJPH.93.9.1552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahay BK, &amp; Sahay RK (2003) Hypertension in diabetes. In Journal of the Indian Medical Association. J Indian Med Assoc. 101 1 12–15+44. https://doi.org/10.5005/jp/books/12593_24</Citation>
        </Reference>
        <Reference>
          <Citation>Sakano D, Shiraki N, Kikawa K, Yamazoe T, Kataoka M, Umeda K, Araki K, Mao D, Matsumoto S, Nakagata N, Andersson O, Stainier D, Endo F, Kume K, Uesugi M, Kume S (2014) VMAT2 identified as a regulator of late-stage β-cell differentiation. Nat Chem Biol 10(2):141–148. https://doi.org/10.1038/nchembio.1410</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.1410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sallis JF, Floyd MF, Rodríguez DA, Saelens BE (2012) Role of built environments in physical activity, obesity, and cardiovascular disease. Circulation 125(5):729–737. https://doi.org/10.1161/CIRCULATIONAHA.110.969022</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.969022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulz M, Romppel M, Grande G (2016) Built environment and health: a systematic review of studies in Germany. J Public Health 40(1):8–15. https://doi.org/10.1093/pubmed/fdw141</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/pubmed/fdw141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulz M, Romppel M, &amp; Grande G (2018) Built environment and health: a systematic review of studies in Germany. In Journal of Public Health (United Kingdom). Oxford University Press. 40 1 8–15. https://doi.org/10.1093/pubmed/fdw141</Citation>
        </Reference>
        <Reference>
          <Citation>Scott RA, Langenberg C, Sharp SJ, Franks PW, Rolandsson O, Drogan D, van der Schouw YT, Ekelund U, Kerrison ND, Ardanaz E, Arriola L, Balkau B, Barricarte A, Barroso I, Bendinelli B, Beulens JWJ, Boeing H, de Lauzon-Guillain B, Deloukas P, … Wareham NJ (2013) The link between family history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the EPIC-InterAct Study. Diabetologia, 56(1), 60. https://doi.org/10.1007/S00125-012-2715-X</Citation>
        </Reference>
        <Reference>
          <Citation>Scranton RE, Gaziano JM, Rutty D, Ezrokhi M, &amp; Cincotta A (2007) A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset<sup>TM</sup> or placebo. BMC Endocr Disord 7. https://doi.org/10.1186/1472-6823-7-3</Citation>
        </Reference>
        <Reference>
          <Citation>Seeman P, &amp; Van Tol HHM (1994) Dopamine receptor pharmacology. In Trends in Pharmacological Sciences. Trends Pharmacol Sci. 15 7 264–270. https://doi.org/10.1016/0165-6147(94)90323-9</Citation>
        </Reference>
        <Reference>
          <Citation>Seino S (2012) Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea. Diabetologia 55(8):2096–2108. https://doi.org/10.1007/S00125-012-2562-9/FIGURES/2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/S00125-012-2562-9/FIGURES/2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharabi K, Tavares CDJ, Rines AK, Puigserver P (2015) Molecular pathophysiology of hepatic glucose production. Mol Aspects Med 46:21. https://doi.org/10.1016/J.MAM.2015.09.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.MAM.2015.09.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma S, Batra S, Gupta S, Sharma VK, Rahman MH, &amp; Kamal MA (2021) Persons with co-existing neurological disorders: risk analysis, considerations and management in COVID-19 pandemic. CNS Neurol Disord-Drug Targets, 20. https://doi.org/10.2174/1871527320666210308113457</Citation>
        </Reference>
        <Reference>
          <Citation>Shivaprasad C, Kalra S (2011) Bromocriptine in type 2 diabetes mellitus. Indian J Endocrinol Metab 15(5):17. https://doi.org/10.4103/2230-8210.83058</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/2230-8210.83058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sindhu RK, Verma R, Salgotra T, Rahman MH, Shah M, Akter R, Murad W, Mubin S, Bibi P, Qusti S, Alshammari EM, Batiha GES, Tomczyk M, &amp; Al-Kuraishy HM (2021) Impacting the remedial potential of nano delivery-based flavonoids for breast cancer treatment. In Molecules. 26 17. https://doi.org/10.3390/molecules26175163</Citation>
        </Reference>
        <Reference>
          <Citation>Soccio RE, Chen ER, Lazar MA (2014) Thazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 20(4):573. https://doi.org/10.1016/J.CMET.2014.08.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.CMET.2014.08.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sokoloff P, &amp; Schwartz JC (1995) Novel dopamine receptors half a decade later. In Trends in Pharmacological Sciences. Trends Pharmacol Sci. 16 8 270–275. https://doi.org/10.1016/S0165-6147(00)89044-6</Citation>
        </Reference>
        <Reference>
          <Citation>Sola D, Rossi L, Schianca GPC, Maffioli P, Bigliocca M, Mella R, Corlianò F, Paolo Fra G, Bartoli E, Derosa G (2015) Sulfonylureas and their use in clinical practice. Arch Med Sci: AMS 11(4):840. https://doi.org/10.5114/AOMS.2015.53304</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/AOMS.2015.53304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solis-Herrera C, Triplitt C, Cersosimo E, &amp; DeFronzo RA (2021) Pathogenesis of type 2 diabetes mellitus.</Citation>
        </Reference>
        <Reference>
          <Citation>Sørensen M, Hjortebjerg D, Eriksen KT, Ketzel M, Tjønneland A, Overvad K, Raaschou-Nielsen O (2015) Exposure to long-term air pollution and road traffic noise in relation to cholesterol: a cross-sectional study. Environ Int 85:238–243. https://doi.org/10.1016/j.envint.2015.09.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.envint.2015.09.021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Southern LL, Cincotta AH, Meier AH, Bidner TD, Watkins KL (1990) Bromocriptine-induced reduction of body fat in pigs. J Anim Sci 68(4):931–936. https://doi.org/10.2527/1990.684931x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2527/1990.684931x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sunahara RK, Guan HC, O’Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HHM, Niznik HB (1991) Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350(6319):614–619. https://doi.org/10.1038/350614a0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/350614a0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suski, V., &amp; Stacy, M. (2013). Dopamine agonists. In Handbook of Parkinson’s Disease, Fifth Edition. CRC Press. pp. 414–429. https://doi.org/10.5005/jp/books/10587_26</Citation>
        </Reference>
        <Reference>
          <Citation>Tagde P, Tagde P, Tagde S, Bhattacharya T, Garg V, Akter R, Rahman MH, Najda A, Albadrani GM, Sayed AA, Akhtar MF, Saleem A, Altyar AE, Kaushik D, &amp; Abdel-Daim MM (2021) Natural bioactive molecules: an alternative approach to the treatment and control of glioblastoma multiforme. In Biomedicine and Pharmacotherapy 141). https://doi.org/10.1016/j.biopha.2021.111928</Citation>
        </Reference>
        <Reference>
          <Citation>Taghavi SM, Fatemi SS, Rokni H (2012) Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure. Med J Malaysia 67(4):390–392</Citation>
        </Reference>
        <Reference>
          <Citation>Tan JR, Chen YH, Bi YF, Xu M, Huang Y, Dai M, Ning G, Li XY (2010) Prehypertension is associated with atherosclerosis in type 2 diabetes. J Diabetes 2(1):56–63. https://doi.org/10.1111/j.1753-0407.2009.00062.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1753-0407.2009.00062.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tiberi M, Jarvie KR, Silvia C, Falardeau P, Gingrich JA, Godinot N, Bertrand L, Yang-Feng TL, Fremeau RT, Caron MG (1991) Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. Proc Natl Acad Sci USA 88(17):7491–7495. https://doi.org/10.1073/pnas.88.17.7491</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.88.17.7491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuomi T, Santoro N, Caprio S, Cai M, Weng J, &amp; Groop L (2014) The many faces of diabetes: a disease with increasing heterogeneity. In The Lancet. Lancet Publishing Group. 383 9922 1084–1094. https://doi.org/10.1016/S0140-6736(13)62219-9</Citation>
        </Reference>
        <Reference>
          <Citation>Ustione A, Piston DW (2012) Dopamine synthesis and D3 receptor activation in pancreatic β-cells regulates insulin secretion and intracellular [Ca2+] oscillations. Mol Endocrinol 26(11):1928–1940. https://doi.org/10.1210/ME.2012-1226</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/ME.2012-1226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallon V, Thomson SC (2017) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60(2):215–225. https://doi.org/10.1007/S00125-016-4157-3/FIGURES/3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/S00125-016-4157-3/FIGURES/3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Hilten JJ, Ramaker CC, Stowe RL, &amp; Ives NJ (2007) Bromocriptine versus levodopa in early Parkinson’s disease. In Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd. (4). https://doi.org/10.1002/14651858.CD002258.pub2</Citation>
        </Reference>
        <Reference>
          <Citation>van Stee MF, de Graaf AA, Groen AK (2018) Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovasc Diabetol 17(1):1–22. https://doi.org/10.1186/S12933-018-0738-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/S12933-018-0738-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vermund SH, Goldstein RG, Romano AA, Atwood SJ (1984) Accidental bromocriptine ingestion in childhood. J Pediatr 105(5):838–840. https://doi.org/10.1016/S0022-3476(84)80319-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0022-3476(84)80319-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Via (2010) Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes, Metab Syndr Obes: Targets and Therapy 3:43. https://doi.org/10.2147/dmsott.s9575</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/dmsott.s9575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walia V, Kaushik D, Mittal V, Kumar K, Verma R, Parashar J, Akter R, Rahman MH, Bhatia S, Al-Harrasi A, Karthika C, Bhattacharya T, Chopra H, &amp; Ashraf GM (2021) Delineation of neuroprotective effects and possible benefits of antioxidants therapy for the treatment of Alzheimer’s diseases by targeting mitochondrial-derived reactive oxygen species: bench to bedside. In Molecular Neurobiology. https://doi.org/10.1007/s12035-021-02617-1</Citation>
        </Reference>
        <Reference>
          <Citation>Wasada T, Kawahara R, &amp; Iwamoto Y (2000) Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. In Diabetes Care. American Diabetes Association Inc. 23 7 1039–1040. https://doi.org/10.2337/diacare.23.7.1039</Citation>
        </Reference>
        <Reference>
          <Citation>Webb EA, Hesseling AC, Schaaf HS, Gie RP, Lombard CJ, Spitaels A, Delport S, Marais BJ, Donald K, Hindmarsh P, Beyers N (2009) High prevalence of Mycobacterium tuberculosis infection and disease in children and adolescents with type 1 diabetes mellitus. Int J Tuberc Lung Dis 13(7):868–874</Citation>
        </Reference>
        <Reference>
          <Citation>Well C (1986) The safety of bromocriptine in long-term use: a review of the literature. Curr Med Res Opin 10(1):25–51. https://doi.org/10.1185/03007998609111089</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1185/03007998609111089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wendel-Vos W, Droomers M, Kremers S, Brug J, Van Lenthe F (2007) Potential environmental determinants of physical activity in adults: a systematic review. Obes Rev 8(5):425–440. https://doi.org/10.1111/j.1467-789X.2007.00370.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1467-789X.2007.00370.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiggins J, Skinner C (1986) Bromocriptine induced pleuropulmonary fibrosis. Thorax 41(4):328–330. https://doi.org/10.1136/thx.41.4.328</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/thx.41.4.328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willi C, Bodenmann P, Ghali WA, Faris PD, &amp; Cornuz J (2007) Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. In Journal of the American Medical Association. JAMA. 298 22 2654–2664. https://doi.org/10.1001/jama.298.22.2654</Citation>
        </Reference>
        <Reference>
          <Citation>Wu Y, Ding Y, Tanaka Y, Zhang W (2014) Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci 11(11):1185. https://doi.org/10.7150/IJMS.10001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/IJMS.10001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Zhao C, Ye Y, Yu M, Qu X (2020) Prospect of sodium–glucose co-transporter 2 inhibitors combined with insulin for the treatment of type 2 diabetes. Front Endocrinol 11:190. https://doi.org/10.3389/FENDO.2020.00190/BIBTEX</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/FENDO.2020.00190/BIBTEX</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yonemochi N, Ardianto C, Yang L, Yamamoto S, Ueda D, Kamei J, Waddington JL, Ikeda H (2019) Dopaminergic mechanisms in the lateral hypothalamus regulate feeding behavior in association with neuropeptides. Biochem Biophys Res Commun 519(3):547–552. https://doi.org/10.1016/J.BBRC.2019.09.037</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.BBRC.2019.09.037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong J, Rao X, Rajagopalan S (2013) An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 226(2):305–314. https://doi.org/10.1016/J.ATHEROSCLEROSIS.2012.09.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.ATHEROSCLEROSIS.2012.09.012</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
